alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,076–1,100 of 1,102 studies published 2018 (page 44 of 45) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Network pharmacology-based analysis of Chinese herbal Naodesheng formula for application to Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Chinese journal of natural medicines 2018-01-01

Naodesheng (NDS) formula, which consists of Rhizoma Chuanxiong, Lobed Kudzuvine, Carthamus tinctorius, Radix Notoginseng, and Crataegus pinnatifida, is widely applied for the treatment of cardio/cerebrovascular ischemic diseases, ischemic stroke, and sequelae of cerebral hemorrhage, etc. At present, the studies on NDS formula for Alzheimer's disease (AD) only focus on single component of this prescription, and there is no report about the synergistic mechanism of the constituents in NDS formula for the potential treatment of dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

In-hospital dementia-related deaths following implementation of the national dementia plan: observational study of national death certificates from 1996 to 2016

✓ Peer-reviewed alzhub usefulness score 37 out of 100. BMJ Open 2018-12-01

The annual number of deaths at hospital was consistently increased over time from 1996 to 2016 (age-adjusted OR: 6.01; 95% CI 5.81 to 6.21 versus home deaths). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Oral Presentations of the 2018 Annual Meeting of the Congress of Neurological Surgeons

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Neurosurgery 2018-08-17

Our robust machine learning based analytical pipeline consists of segmentation, radiomic texture extraction, feature normalization and selection, and predictive-model generation. 5 key findings →

Participants: 40 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Glial alterations in human prion diseases: A correlative study of astroglia, reactive microglia, protein deposition, and neuropathological lesions

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Medicine 2018-04-01

Proteinopathies such as Alzheimer, Parkinson, and Huntington diseases, where aberrant proteins spread throughout the brain during disease progression, may share a molecular basis and mechanisms of propagation. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Molecular syndromology 2018-10-30

In the last decade, a number of important research advances in different fields have allowed Down syndrome (DS) research to flourish, creating a time of both unparalleled opportunity and considerable challenge. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

On the way to precision formulation additives: 2D-screening to select solubilizers with tailored host and release capabilities

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of controlled release : official journal of the Controlled Release Society 2018-06-28

A 2-dimensional high-throughput screening method is presented to select peptide sequences from large peptide libraries for precision formulation additives, having a high capacity to specifically host a drug of interest and provide tailored drug release properties. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The “American (cancer) patients first” plan to reduce drug prices—A critical assessment

✓ Peer-reviewed alzhub usefulness score 36 out of 100. American Journal of Hematology 2018-09-16

Serious concerns over the rising cost of cancer drugs in the United States1-3 are increasing,4-9 following a decade during which prices rose from an average of less than $10 000/year to more than $170 000/year in 2017.10 Despite the drug industry's wish to be “part of the solution,” the problem continues to worsen.6 Between 1995 and 2013, the launch price of cancer drugs increased by 10%-12% every year.11 According to a March 2018 report, the Average Wholesale Prices of drugs increased at unprecedented rates.12 A study by Gordon and colleagues showed a 25% average annual price increase of drugs already on the market, despite competition.13 Cancer drugs spending doubled since 2013 and is expected to double again by 2022.14 This suggests that health care is different from other industries where traditional free market forces are effective in lowering prices, and that other measures are needed. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Metabolic Syndrome Exacerbates the Recognition Memory Impairment and Oxidative-Inflammatory Response in Rats with an Intrahippocampal Injection of Amyloid Beta 1-42

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Oxidative medicine and cellular longevity 2018-08-01

An important worldwide health problem as the result of current lifestyle is metabolic syndrome (MS). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Fluoride activates microglia, secretes inflammatory factors and influences synaptic neuron plasticity in the hippocampus of rats

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Neurotoxicology 2018-09-28

Epidemiological studies have reported that highly fluoridated drinking water may significantly decrease the Intelligence Quotient (IQ) of exposed children. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Hypercapnic and Hypoxic Respiratory Response During Wakefulness and Sleep in a Streptozotocin Model of Alzheimer's Disease in Rats

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01

Besides the typical cognitive decline, patients with Alzheimer's disease (AD) develop disorders of the respiratory system, such as sleep apnea, shortness of breath, and arrhythmias. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer’s disease progression that reinforces the 2018 NIA-AA research framework

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Journal of Alzheimer's disease : JAD 2018-10-15

The 2018 NIA-AA research framework proposes a classification system with beta- A myloid deposition, pathologic T au, and n eurodegeneration (ATN) for the diagnosis and staging of Alzheimer’s Disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

[Quercetin ameliorates inflammation in CA1 hippocampal region in aged triple transgenic Alzheimer´s disease mice model.]

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Biomedica : revista del Instituto Nacional de Salud 2018-05-01

Our work suggests an anti-inflammatory effect of quercetin in the CA1 hippocampal region of aged triple transgenic Alzheimer's disease mice. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Elimination of amyloid precursor protein in senile plaques in the brain of a patient with Alzheimer-type dementia and Down syndrome

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Brain & development 2018-08-04

The average lifespan of individuals with Down syndrome has approximately doubled over the past three decades to 55-60 years. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The new paradigm in community-based care: Managing mindset and expectations

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Journal of Emergencies Trauma and Shock 2018-01-01

Some of the considerations that need to be taken into account in coming to a decision include: Disease prevalence and burden in the country The existing health-care model and system The ratio of health-care providers to patient Cost and health-care funding in the country The current and projected health-care demand and needs The perception of the population on FP s and primary care providers versus that of specialists in hospitals and The networks and strengths of the primary care model in the country. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

RICHMOND HEALTH AND WELLNESS PROGRAM: COMMUNITY ADVISORY COUNCIL OUTCOMES

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Innovation in Aging 2018-11-01

The Richmond Health and Wellness Program (RHWP) provides interprofessional care coordination and wellness services within Richmond’s low income senior housing communities for approximately 1,000 subsidized housing units. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed